Chemours CO Form 4 insider transactions

David Will, Chief Accounting Officer of Chemours Co, reported a transaction in 2,426 shares of common stock on August 12, 2026.

Calderon Gerardo Familiar, See Remarks of Chemours Co, purchased 1,935 shares of common stock on August 12, 2026 for $15.53 per share.

Denise Dignam, Chief Executive Officer and a Director of Chemours Co, purchased 3,378 shares of common stock on August 11, 2026 for $14.95 per share.

Michael Robert Foley, See Remarks of Chemours Co, purchased 1,934 shares of common stock on August 7, 2026 for $15.51 per share.

Alister Cowan, a Director of Chemours Co, purchased 13,000 shares of common stock on August 7, 2026 for $15.62 per share.

Mary B Cranston, a Director of Chemours Co, purchased 6,000 shares of common stock on August 7, 2026 for $15.82 per share.

Joseph T. Martinko, See Remarks of Chemours Co, purchased 1,940 shares of common stock on August 7, 2026 for $15.47 per share.

Calderon Gerardo Familiar, See Remarks of Chemours Co, reported a transaction in 943 shares of common stock on August 1, 2026.

Joseph T. Martinko, See Remarks of Chemours Co, reported a transaction in 663 shares of common stock on August 1, 2026.

Courtney Mather, a Director at The Chemours Company, reported transactions involving deferred stock units on June 30, 2026.

Director Mary Cranston acquired 7,182 shares of Chemours common stock, bringing her total beneficial ownership to 106,830.0129 shares.

Chemours Company Director Pamela Fletcher acquired 7,182 stock units as part of board compensation.

Chemours Company Director Alister Cowan acquired 7,182 stock units as part of board compensation.

Chemours Company Director Courtney Mather acquired 7,182 stock units as part of board compensation.

Chemours Company Director Erin N. Kane acquired 7,182 stock units as part of board compensation.

Director Livingston Satterthwaite acquired 7,182 stock units in The Chemours Company as part of board compensation.

Director Sean D. Keohane acquired 7,182 stock units in The Chemours Company as part of a board compensation arrangement.

Director Joseph Kava acquired 7,182 stock units in The Chemours Company as part of a board compensation arrangement.

Director George R. Brokaw acquired 7,182 shares of Chemours Co common stock as part of an equity grant.

Chemours Director Courtney Mather acquired 1,305 deferred stock units, increasing beneficial ownership to 7,552.3528 units.

Chemours SVP Kristine Wellman reported the acquisition of 25,708 shares via an RSU award and the disposition of 3,359 shares for tax obligations.

A Chemours Company executive, Gerardo Familiar Calderon, received a new RSU award of 25,708 shares, while 2,635 shares were withheld for tax obligations.

Chemours CEO Denise Dignam reported changes in her beneficial ownership, including tax-related share withholding and a new RSU award.

Michael Robert Foley, President of Titanium Technologies at Chemours Co, was granted 75,040 Restricted Stock Units (RSUs) on March 2, 2026, as part of his compensation.

Joseph T. Martinko, President of Thermal & Specialized Solutions at Chemours Co, reported the acquisition of 28,488 Restricted Stock Units and the withholding of 2,789 shares for tax obligations.

Chemours CFO Shane Hostetter reported an increase in beneficial ownership following RSU awards and tax-related share withholding.

The Chemours Company's Chief Accounting Officer, David Will, reported a routine grant of restricted stock units and shares withheld for tax obligations.

Chemours SVP Kristine Wellman reported the vesting of performance stock units and subsequent tax-related share withholding, adjusting her beneficial ownership.

Chemours CEO Denise Dignam reported the vesting of performance stock units and subsequent withholding of shares for tax obligations.

Chemours Director Livingston Satterthwaite acquired 1,298 deferred stock units, increasing his beneficial ownership to 4,615.309 units, as part of a pre-arranged plan.